Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $12.13 and last traded at $12.17, with a volume of 122639 shares traded. The stock had previously closed at $12.28.
Wall Street Analyst Weigh In
MYGN has been the subject of a number of analyst reports. StockNews.com raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $30.00 to $21.00 in a report on Monday, December 9th. Piper Sandler dropped their target price on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, UBS Group began coverage on Myriad Genetics in a report on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price target for the company. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $23.92.
View Our Latest Research Report on Myriad Genetics
Myriad Genetics Trading Up 0.5 %
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.08). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $213.30 million for the quarter, compared to analyst estimates of $209.82 million. During the same quarter in the prior year, the business earned ($0.17) EPS. Research analysts anticipate that Myriad Genetics, Inc. will post -0.28 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Myriad Genetics
Large investors have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new stake in Myriad Genetics in the third quarter valued at approximately $32,000. GAMMA Investing LLC grew its stake in shares of Myriad Genetics by 34.1% in the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after buying an additional 412 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Myriad Genetics in the 2nd quarter valued at $60,000. KBC Group NV lifted its stake in Myriad Genetics by 132.8% during the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after acquiring an additional 3,334 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Myriad Genetics during the 2nd quarter valued at about $82,000. Institutional investors and hedge funds own 99.02% of the company’s stock.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Further Reading
- Five stocks we like better than Myriad Genetics
- How to Find Undervalued Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- How to Capture the Benefits of Dividend Increases
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.